Polysaccharide biomedical colloidal fluid and preparation method

A biomedical and colloid technology, applied in the field of polysaccharide biomedical colloid, can solve the problems of unsatisfactory patients, poor curative effect of market products, no obvious promotion of wound healing, etc., to control infection and deterioration, inhibit bacterial migration, and achieve large clinical The effect of applying value

Inactive Publication Date: 2015-12-02
任汉学
View PDF4 Cites 10 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In the 1960s, most of the wound dressings used for more than half a century were gauze. Gauze was mostly made of cotton, burlap and linen. It was an inert dressing, and its design concept was to absorb, eliminate wound exudate and isolate the wound. effect, no significant effect on wound healing
There are few natural biological cell repair products for wound healing at home and abroad, and the curative effect of market products is poor, which cannot meet the needs of patients

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0012] A kind of biological colloid liquid, biological colloid liquid comprises by weight percentage: sodium carboxymethyl cellulose 0.75%, sodium chloride 1.1%, carbomer 1.25%, sodium hyaluronate 0.3%, phytic acid 0.045%, seaweed Sodium phosphate 0.025%, glycerol 0.14%, chitosan oligosaccharide 0.16%, polyhexamethylene guanidine 0.18%, licorice extract 0.11%, and the rest are water for injection. The preparation method comprises the following steps: dissolving sodium chloride in water for injection , then add sodium carboxymethylcellulose and sodium alginate to the water, turn on the incubator, and stir mechanically at a temperature of 60°C until the sodium carboxymethylcellulose is completely dissolved to obtain solution A; add phytic acid, glycerol, Oligochitosan, carbomer, sodium hyaluronate, polyhexamethylene guanidine, licorice extract and water for injection are mixed to obtain solution B; after mixing solution B and A evenly, filling and packaging are obtained Polysacc...

Embodiment 2

[0014] A kind of biological colloid liquid, described colloid liquid comprises by weight percentage: sodium carboxymethyl cellulose 9.8%, sodium chloride 1.45%, carbomer 0.65%, sodium hyaluronate 0.35%, phytic acid 0.036%, Sodium alginate 0.055%, glycerin 0.16%, chitosan oligosaccharide 0.18%, polyhexamethylene guanidine 0.19%, licorice extract 0.05%, and the rest is water for injection. The preparation method comprises the following steps: dissolving sodium chloride in injection Water, then add carboxymethylcellulose sodium and sodium alginate to the water, turn on the incubator, and mechanically stir at a temperature of 85°C until the carboxymethylcellulose sodium is completely dissolved to obtain solution A; add phytic acid, glycerol , chitosan oligosaccharide, carbomer, sodium hyaluronate, polyhexamethylene guanidine, licorice extract and water for injection are mixed to obtain solution B; after mixing solution B and A evenly, it is filled and packaged The polysaccharide b...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses polysaccharide biomedical colloid. The colloidal fluid is prepared from, by weight, 0.5-10% of sodium carboxymethyl cellulose, 0.5-1.5% of sodium chloride, 0.5-1.5% of carbomer, 0.08-0.7% of sodium hyaluronate, 0.01-0.05% of phytate, 0.02-0.1% of sodium alginate, 0.1-0.3% of glycerol, 0.15-0.45% of chitobiose, 0.15-0.35% of polyhexamethylene guanidine, 0.01-0.2% of liquorices extract and the balance water used for injection. By means of formula optimization, the polysaccharide biomedical colloid is free of toxic and side effects, has great clinical application value, is short in healing time and high in healing rate, forms a wound surface wet environment, can directly restrain scar forming when used for cell repairing, and can form a wound surface protection film, block injuries caused by bacteria to wound surfaces, and restrain the adsorption process, the multiplication process, the copying process and other processes of bacteria on wound surfaces.

Description

technical field [0001] The invention relates to a polysaccharide biomedical colloid. Background technique [0002] For more than a century, western medicine has mainly treated wounds (skin) by applying dressings to cover wounds. In theory, wound dressings can prevent microbial contamination of wounds and prevent infection from spreading to other patients. In clinical applications, dressings also mainly play a role as a barrier . Furthermore, the composition and characteristics of the dressing itself can play a role in regulating the microenvironment of the wound. In the 1960s, most of the wound dressings used for more than half a century were gauze. Gauze was mostly made of cotton, burlap and linen. It was an inert dressing, and its design concept was to absorb, eliminate wound exudate and isolate the wound. It has no obvious promoting effect on wound healing. The research on dressing materials is also mainly considered from the aspects of biological inertness, non-toxici...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K36/484A61P17/02A61P31/02A61L26/00A61K31/728A61K31/734A61K31/722
Inventor 任汉学
Owner 任汉学
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products